AR and posterior cortical atrophy: ASC‐J9®, the first AR (androgen receptor) degradation enhancer8, 9, 10 that could selectively degrade AR in selective cells, has been demonstrated to be able to suppress several AR‐related tumors including prostate, bladder, kidney and liver with few side effects.11, 12, 13 It has also been shown that ASC‐J9® could have AR independent effects such as direct inhibition of STAT3 phosphorylation in AR‐negative PCa cells.14 Its potential influence over Sorafenib therapy, however, remains unclear.